Vahideh Montazeri
@smums.ac.ir
Smart University of Medical Sciences
RESEARCH INTERESTS
Molecular Pharmacology, Cancer System Biology, Cancer Stem cells, Medical Education, E-Learning
Scopus Publications
Scopus Publications
Nima Rastegar-Pouyani, Vahideh Montazeri, Nikoo Marandi, Shima Aliebrahimi, Melika Andalib, Emad Jafarzadeh, Hamed Montazeri, and Seyed Nasser Ostad
Informa UK Limited
This study comparatively evaluated the possible effects of recurrent and non-recurrent patient-derived Cancer-Associated Fibroblasts (CAFs-R and -NR) on the bladder cancer cell line, EJ138. Both groups of CAFs increased cisplatin resistance and altered cell cycle distribution alongside induced resistance to apoptosis. Later, the scratch assay confirmed the cell migration-inducing effects of CAFs on cells. Nonetheless, only CAFs-R managed to increase sphere-formation and clonogenic levels in EJ138 cells, which were later validated by upregulating pluripotency transcription factors. Besides, CAFs-R also affected the expression levels of some of the EMT markers. Our study suggests that CAFs-R had stronger pro-tumorigenic effects on EJ138 cells.
Sepideh Yoosefi, Amir Rakhshani, Vahideh Montazeri, Mohamadreza Tavakoli, Amin Aliabadi, Yousef Fatahi, Helia Behrouzfar, Shadi Keihankhadiv, Behzad Darbasizadeh, Hamidreza Motasadizadeh,et al.
Elsevier BV
Peymaneh Habibi, Seyed Nasser Ostad, Mohammad Reza Monazzam, Abbas Rahimi Foroushani, Mahmoud Ghazi-Khansari, Shima Aliebrahimi, Vahideh Montazeri, and Farideh Golbabaei
Springer Science and Business Media LLC
Peymaneh Habibi, Seyed Naser Ostad, Ahad Heydari, Shima Aliebrahimi, Vahideh Montazeri, Abbas Rahimi Foroushani, Mohammad Reza Monazzam, Mahmoud Ghazi-Khansari, and Farideh Golbabaei
Springer Science and Business Media LLC
Emad Jafarzadeh, Vahideh Montazeri, Shima Aliebrahimi, Ahmad Habibian Sezavar, Mohammad H. Ghahremani, and Seyed Nasser Ostad
Elsevier BV
Seyede Masoome Sajjadi Mohri, Vahideh Montazeri, Shima Aliebrahimi, Anita Abedi, Marzieh Zare Dehnavi, Akram Jamshidzade, and Seyed Nasser Ostad
Knowledge E DMCC
According to the cancer stem cell (CSC) theory, a subpopulation of cells demonstrating stem-like cell properties is responsible for tumorigenicity, self-renewal capacity, therapeutic resistance, and recurrence. Due to the resistance of CSCs, it is necessary to develop drugs with appropriate efficacy. Although cisplatin is a potent antitumor agent widely used in the treatment of different cancers, its severe side effects and resistance remain a challenge in clinical practice. Research has shown that platinum (IV) has considerably fewer side effects and is associated with much less drug resistance. In this study, the toxicity and effectiveness of [Pt(dpyam)Cl4], where dpyam is 2,2'-dipyridylamine as a platinum (IV) agent, was investigated to find a reliable alternative to cisplatin. For this purpose, cancer stem-like cells (CS-LCs) with CD44+/CD133+ phenotype were isolated from HT1080 cells. EJ138, HT1080, and CS-LCs derived from HT1080 cells were selected to compare the effectiveness of Pt (IV) complex versus cisplatin. MTT, apoptosis, and cell cycle analysis were carried out to evaluate drug toxicity. Sphere and colony formation assays confirmed the potentiality of Pt (IV) complex and cisplatin to target stemness characteristics of CS-LCs. Although toxicity results were in favor of cisplatin, the anticancer activity of the synthesized Pt (IV) complex was also considerable. Regarding other studies that proposed high selective toxicity of Pt (IV), it could be a candidate for additional improvements.
Amir Farnudian-Habibi, Mobina Mirjani, Vahideh Montazer, Shima Aliebrahimi, Iman Katouzian, Saeed Abdolhosseini, Ali Rahmani, Hossein Keyvani, Seyed Nasser Ostad, and Mazda Rad-Malekshahi
Briefland
: The last generation of Coronavirus named COVID-19 is responsible for the recent worldwide outbreak. Concerning the widespread and quick predominance, there is a critical requirement for designing appropriate vaccines to surmount this grave problem. Correspondingly, in this revision, COVID-19 vaccines (which are being developed until March 29th, 2021) are classified into specific and non-specific categories. Specific vaccines comprise genetic-based vaccines (mRNA, DNA), vector-based, protein/recombinant protein vaccines, inactivated viruses, live-attenuated vaccines, and novel strategies including microneedle arrays (MNAs), and nanoparticles vaccines. Moreover, specific vaccines such as BCG, MRR, and a few other vaccines are considered Non-specific. What is more, according to the significance of Bioinformatic sciences in the cutting-edge vaccine design and rapid outbreak of COVID-19, herein, Bioinformatic principles including reverse vaccinology, epitopes prediction/selection and, their further applications in the design of vaccines are discussed. Last but not least, safety, challenges, advantages, and future prospects of COVID-19 vaccines are highlighted.
Azadeh Rasouli, Shima Aliebrahimi, Vahideh Montazeri, Mohammad Hossein Ghahremani, and Seyed Nasser Ostad
FapUNIFESP (SciELO)
Hypoxia-inducible factors (HIFs) and cancer stem cells (CSCs) are two challenging causes of radiotherapy and chemotherapy resistance, leading to most cases of failure and recurrence in breast cancer therapy. This study was conducted to investigated the inhibitory effect of combination therapy with doxorubicin (an anthracycline) and FM19G11 (an HIF inhibitor) on MCF-7 cells and their CSC-like cells (CSC-LCs). MCF-7 CSC-LCs with a CD44 + /CD24 - phenotype were sorted and characterized by flow cytometry. A combination of doxorubicin and FM19G11 caused more cytotoxic effects on MCF-7 and CSC-LCs compared to doxorubicin monotherapy. The largest synergistic effect was observed in CSC-LCs under hypoxic conditions; however, MCF-7 cells showed no synergism in normoxic conditions. The administration of doxorubicin and FM19G11 induced late apoptotic and necrotic cell death in MCF-7 and CSC-LCs. Additionally, G2 phase arrest was observed in both cells. Our results demonstrated that co-administration of FM19G11 and doxorubicin had a synergistic effect in hypoxia and improved drug resistance in breast cancer stem cells.
V. Montazeri, M. Ghahremani, H. Montazeri, M. Hasanzad, D. Safavi, M. Ayati, M. Chehrazi, Baharak Arefi Moghaddam and S. Ostad
One of the main genotoxic drugs used in bladder cancer chemotherapy is cisplatin. While it is applied in most types of cancers, resistance to cisplatin is wildly common. In order to overcome drug resistance, it is necessary to determine a predictive marker. This study was conducted to provide basic data for selecting and designing a gene profile for further cohort and RCT studies in the future to improve response to treatment in bladder cancer. The expression levels of ERCC1, MLH1, MSH2, and CTR1 mRNA were determined in the tumor tissue using real-time q-PCR. Progression-free survival (PFS) was analyzed in term of the level of genes expression. The results revealed that the level of ERCC1 mRNA expression was higher in the recurrence (R) group compared to the no recurrence (NR) group. Moreover, the PFS time was increased in the patients with an ERCC1 expression level of below 1.57. The level of MLH1 and MSH2 mRNA expression was lower in the R group compared to the NR group; therefore, PFS time was increased in the patients with MLH1 and MSH2 gene expression levels above the cutoff point. While the level of CTR1 mRNA expression was higher in the R group versus the NR group, the PFS time was longer in the patients with CTR1 expression levels of below 1.265 compared to the patients with high levels of CTR1 expression. It can be concluded that the level of ERCC1, MLH1, MSH2, and CTR1 mRNA expression may be associated with PFS time as possible therapeutic targets for decreasing cisplatin resistance.
Mehrnaz Asadi Sarighieh, Vahideh Montazeri, Amir Shadboorestan, Mohammad Hossein Ghahremani, and Seyed Nasser Ostad
Georg Thieme Verlag KG
AbstractHypoxia in the microenvironment is related to chemotherapy resistance, tumor progression, and metastasis. Curcumin, as a phenolic compound extracted from the turmeric, has been used as an anti-cancer agent with low toxicity in recent years. Since curcumin has inhibitory activities against hypoxia-inducible factors (HIFs) in several cancers, this study was conducted to examine the effect of curcumin on MCF-7 cells and cancer stem-like cells (CS-LCs) under hypoxic and normoxic conditions. CS-LCs were isolated from MCF-7 cells using the magnet activated cell sorting (MACS) method based on CD44 +/ CD24 - surface markers. The effects of curcumin on the viability of MCF-7 cells and CS-LCs were examined in hypoxic and normoxic conditions using the MTT test. The effects of curcumin on apoptosis and cell cycle of CS-LCs and MCF-7 cells were analyzed using flow cytometry. Moreover, the inhibitory effects of curcumin on the levels of HIF-1 and HIF-2α protein in CS-LCs were investigated using the western blot method. Early apoptosis occurred in CSC-LCs more than MCF-7 cells under hypoxic conditions. Flow cytometry assay showed that curcumin caused cell cycle arrest of CSC-LCs and MCF-7 at the G2/M phase under hypoxic conditions while under normoxic conditions, arrest occurred at the G0/G1 phase in MCF-7 cells and at S and G2/M phases in CS-LCs. Based on the results, the curcumin inhibited the expression of HIF-1 by degrading ARNT in CS-LCs.In conclusion, curcumin has inhibitory effects on MCF- 7 cells and CS- LCs and thus may be used as an antitumor agent.
Paniz Khooshemehri, S. H. Jamaldini, S. Ziaee, M. Afshari, M. Sattari, B. Narouie, M. Sotoudeh, V. Montazeri, N. Sarhangi and M. Hasanzad
PURPOSE
Mismatch repair (MMR) is one of the DNA repair systems that correct mispaired bases during DNA replication errors. Polymorphisms in genes can increase susceptibility to the development of prostate cancer (PCa). In this study, we investigated mutL homolog 1 (MLH1) -93G>A (rs1800734) and mutS homolog 3 (MSH3) (rs26279) polymorphisms with the risk of PCa.
MATERIALS AND METHODS
In this study of Iranian population, 175 histopathologically confirmed (PCa) patients and 230 benign prostate hyperplasia (BPH) as the controls were recruited. The genotypes of MLH1 and MSH3 were determined by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) method.
RESULTS
There was no significant difference of MLH1 (P=0.4) and MSH3 (P?=?0.5) genotype distributions among PCa cases and controls. And also patients with PCa were not significant differences compared to those without in stage of cancer, grade of tumor, perineural invasion, and vascular invasion.
CONCLUSION
Our results did not show adequate evidence for any significant association of MLH1 and MSH3 polymorphisms and prostate cancer.
Mandana Hasanzad, Seyed Amir Mohsen Ziaei, Vahideh Montazeri, Mahdi Afshari, Seyed Hamid Jamaldini, Mahdieh Imani, Mahshid Sattari, Leila Hashemian, Seyed Rouhollah Kalantar Moaetamed, and Mohammad Samzadeh
Briefland
Ali Mandegary, Arastoo Saeedi, Aziz Eftekhari, Vahideh Montazeri, and Elham Sharif
Springer Science and Business Media LLC